About Asterias Biotherapeutics (NYSEAMERICAN:AST)
Asterias Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing cell-based therapeutics to treat neurological conditions associated with demyelination, and cellular immunotherapies to treat cancer. Its clinical stage programs include AST-OPC1, an oligodendrocyte progenitor cell population derived from pluripotent stem cells that is in Phase I/IIa clinical trial for spinal cord injuries; AST-VAC2 is a non-patient-specific cancer immunotherapy derived from pluripotent stem cells for the treatment of non-small cell lung cancer; and AST-VAC1, a patient-specific cancer immunotherapy that has completed Phase II clinical trial for the treatment of acute myeloid leukemia. The company was formerly known as BioTime Acquisition Corporation and changed its name to Asterias Biotherapeutics, Inc. in March 2013. Asterias Biotherapeutics, Inc. was founded in 2012 and is headquartered in Fremont, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:AST
CUSIPN/A
Phone+1-510-4563805
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-403.38%
Return on Equity-79.80%
Return on Assets-59.45%
Miscellaneous
EmployeesN/A
Outstanding Shares54,200,000
Asterias Biotherapeutics (NYSEAMERICAN:AST) Frequently Asked Questions
What is Asterias Biotherapeutics' stock symbol?
Asterias Biotherapeutics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AST."
How were Asterias Biotherapeutics' earnings last quarter?
Asterias Biotherapeutics (NYSEAMERICAN:AST) issued its earnings results on Thursday, March, 15th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.15) by $0.03. The biotechnology company had revenue of $0.03 million for the quarter, compared to analysts' expectations of $1.08 million. Asterias Biotherapeutics had a negative return on equity of 79.80% and a negative net margin of 403.38%. View Asterias Biotherapeutics' Earnings History.
When is Asterias Biotherapeutics' next earnings date?
What price target have analysts set for AST?
2 analysts have issued 12 month price targets for Asterias Biotherapeutics' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Asterias Biotherapeutics' stock price to reach $8.50 in the next year. View Analyst Ratings for Asterias Biotherapeutics.
Are investors shorting Asterias Biotherapeutics?
Asterias Biotherapeutics saw a decrease in short interest in March. As of March 29th, there was short interest totalling 3,593,338 shares, a decrease of 1.9% from the March 15th total of 3,661,754 shares. Based on an average daily trading volume, of 317,536 shares, the days-to-cover ratio is currently 11.3 days. Currently, 11.4% of the shares of the stock are sold short.
Who are some of Asterias Biotherapeutics' key competitors?
Some companies that are related to Asterias Biotherapeutics include Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Tiziana Life Sciences (TILS), Pfenex (PFNX), Tissue Regenix Group (TRX), Ergomed (ERGO), Navidea Biopharmaceuticals (NAVB), Rexahn Pharmaceuticals (RNN), Abzena (ABZA), Scancell (SCLP), Actinium Pharmaceuticals (ATNM), AmpliPhi Biosciences (APHB), Cormedix (CRMD), ValiRx (VAL) and Phytopharm (IXI).
Who are Asterias Biotherapeutics' key executives?
Asterias Biotherapeutics' management team includes the folowing people:
- Dr. Katharine E. Spink, Consultant (Age 44)
- Dr. Jane S. Lebkowski Ph.D., Scientific Advisor (Age 62)
- Mr. Stephen L. Cartt, Advisor & Director (Age 55)
- Mr. Michael H. Mulroy, Chief Exec. Officer, Pres & Director (Age 52)
- Mr. Ryan D. Chavez, CFO & Gen. Counsel (Age 42)
Has Asterias Biotherapeutics been receiving favorable news coverage?
News coverage about AST stock has been trending positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Asterias Biotherapeutics earned a news impact score of 0.44 on Accern's scale. They also assigned news coverage about the biotechnology company an impact score of 45.71 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.
How do I buy shares of Asterias Biotherapeutics?
Shares of AST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Asterias Biotherapeutics' stock price today?
One share of AST stock can currently be purchased for approximately $1.30.
How big of a company is Asterias Biotherapeutics?
Asterias Biotherapeutics has a market capitalization of $102.89 million.
How can I contact Asterias Biotherapeutics?
Asterias Biotherapeutics' mailing address is 6300 Dumbarton Cir, FREMONT, CA 94555-3644, United States. The biotechnology company can be reached via phone at +1-510-4563805.
MarketBeat Community Rating for Asterias Biotherapeutics (AST)
MarketBeat's community ratings are surveys of what our community members think about Asterias Biotherapeutics and other stocks. Vote "Outperform" if you believe AST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AST will underperform the S&P 500 over the long term. You may vote once every thirty days.
Asterias Biotherapeutics (NYSEAMERICAN:AST) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading and Institutional Ownership History
Asterias Biotherapeutics (NYSEAMERICAN AST) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 3/26/2018 | Michael H Mulroy | Insider | Buy | 2,839 | $1.76 | $4,996.64 | |  |
| 2/26/2018 | Michael H Mulroy | Insider | Buy | 2,255 | $2.22 | $5,006.10 | | |
| 1/25/2018 | Michael H Mulroy | Insider | Buy | 2,134 | $2.34 | $4,993.56 | | |
| 12/26/2017 | Michael H Mulroy | Insider | Buy | 2,247 | $2.22 | $4,988.34 | | |
| 11/27/2017 | Michael H Mulroy | Insider | Buy | 2,076 | $2.41 | $5,003.16 | | |
| 10/25/2017 | Michael H Mulroy | Insider | Buy | 1,939 | $2.55 | $4,944.45 | | |
| 9/25/2017 | Michael H. Mulroy | Insider | Buy | 1,537 | $3.25 | $4,995.25 | | |
| 1/9/2017 | Edward Wirth | Insider | Sell | 3,415 | $4.60 | $15,709.00 | 3,415 | |
| 1/9/2017 | Katharine E Spink | COO | Sell | 4,781 | $4.60 | $21,992.60 | 4,781 | |
| 10/6/2016 | Edward Wirth | Insider | Sell | 3,415 | $4.12 | $14,069.80 | | |
| 10/6/2016 | Katharine E. Spink | COO | Sell | 4,781 | $4.11 | $19,649.91 | | |
| 9/9/2016 | Edward Wirth | Insider | Sell | 14,760 | $3.52 | $51,955.20 | | |
| 9/9/2016 | Katharine E. Spink | COO | Sell | 19,336 | $3.52 | $68,062.72 | | |
| 6/30/2016 | Stephen Lahue Cartt | CEO | Buy | 10,000 | $2.40 | $24,000.00 | 260,000 | |
| 6/29/2016 | Richard T Lebuhn | Director | Buy | 5,000 | $2.38 | $11,900.00 | 25,000 | |
| 6/10/2016 | Stephen Lahue Cartt | CEO | Buy | 50,000 | $2.93 | $146,500.00 | 250,000 | |
| 6/9/2016 | Alfred D Kingsley | Director | Buy | 4,000 | $2.93 | $11,720.00 | 9,000 | |
| 5/13/2016 | Natale S Ricciardi | Director | Buy | 14,706 | $3.39 | $49,853.34 | 19,706 | |
| 9/16/2015 | Cary Pinkowski | Director | Sell | 409,000 | $0.0150 | $6,135.00 | | |
| 9/15/2015 | Edward Wirth | insider | Sell | 2,880 | $6.00 | $17,280.00 | | |
| 9/15/2015 | Katharine E. Spink | COO | Sell | 3,760 | $6.00 | $22,560.00 | | |
| 9/14/2015 | Cary Pinkowski | Director | Sell | 394,000 | $0.0150 | $5,910.00 | | |
| 6/25/2015 | Andrew Arno | Director | Buy | 5,000 | $4.32 | $21,600.00 | | |
| 2/9/2015 | Pedro Lichtinger | CEO | Buy | 128,205 | $3.90 | $499,999.50 | | |
| 10/1/2014 | Scarsdale Equities Llc | Major Shareholder | Buy | 60,000 | $5.93 | $355,800.00 | | |
(Data available from 1/1/2013 forward)
Asterias Biotherapeutics (NYSEAMERICAN AST) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Asterias Biotherapeutics (AST) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 20 at 1:54 PM |
| Asterias Biotherapeutics (AST) PT Set at $12.00 by HC Wainwright
www.americanbankingnews.com - April 19 at 12:16 PM |
 | Asterias Biotherapeutic: Spinal Injury Stem Cell Therapy Play
seekingalpha.com - April 18 at 10:40 AM |
| Short Interest in Asterias Biotherapeutics (AST) Declines By 1.9%
www.americanbankingnews.com - April 11 at 2:27 AM |
| Asterias Biotherapeutics (AST) Given a $12.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 10 at 11:38 PM |
| Asterias Biotherapeutics (AST) Given a $12.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 10 at 9:45 AM |
| ValuEngine Upgrades Asterias Biotherapeutics (AST) to Hold
www.americanbankingnews.com - April 9 at 7:30 PM |
| HC Wainwright Reaffirms "Buy" Rating for Asterias Biotherapeutics (AST)
www.americanbankingnews.com - April 8 at 2:04 PM |
| Q1 2018 EPS Estimates for Asterias Biotherapeutics Inc Lifted by Analyst (AST)
www.americanbankingnews.com - March 30 at 6:50 AM |
| Equities Analysts Offer Predictions for Asterias Biotherapeutics Inc's Q1 2019 Earnings (AST)
www.americanbankingnews.com - March 29 at 8:28 AM |
| B. Riley Analysts Give Asterias Biotherapeutics (AST) a $6.00 Price Target
www.americanbankingnews.com - March 27 at 10:27 AM |
| Asterias Biotherapeutics Inc (AST) Sees Large Growth in Short Interest
www.americanbankingnews.com - March 26 at 6:54 PM |
| Asterias Biotherapeutics (AST) PT Set at $6.00 by B. Riley
www.americanbankingnews.com - March 24 at 2:45 PM |
| Asterias Biotherapeutics (AST) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 20 at 5:56 PM |
| Asterias Biotherapeutics (AST) Given a $11.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 16 at 7:47 PM |
 | Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments - GlobeNewswire (press release)
globenewswire.com - March 16 at 3:37 PM |
| Asterias Biotherapeutics' (AST) CEO Mike Mulroy on Q4 2017 Results - Earnings Call Transcript
seekingalpha.com - March 16 at 10:59 AM |
 | Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Developments
finance.yahoo.com - March 16 at 10:59 AM |
| Asterias Biotherapeutics Inc Class A to Host Earnings Call
finance.yahoo.com - March 15 at 3:37 PM |
| Is Astarta Holding NV.’s (WSE:AST) Balance Sheet A Threat To Its Future?
finance.yahoo.com - March 13 at 9:42 AM |
| Asterias Biotherapeutics (AST) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - March 10 at 8:04 PM |
| Asterias Biotherapeutics Inc (AST) Short Interest Update
www.americanbankingnews.com - March 9 at 6:22 PM |
| Asterias Biotherapeutics to Report Fourth Quarter and Full Year ... - GlobeNewswire (press release)
globenewswire.com - March 9 at 3:42 PM |
| Asterias Biotherapeutics to Report Fourth Quarter and Full Year 2017 Results on March 15, 2018
finance.yahoo.com - March 9 at 10:19 AM |
 | Asterias Biotherapeutics (AST) Reports Update on AST-OPC1 ... - StreetInsider.com
www.streetinsider.com - March 1 at 3:33 PM |
| Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
finance.yahoo.com - March 1 at 10:34 AM |
| Asterias Biotherapeutics Inc (AST) Sees Significant Growth in Short Interest
www.americanbankingnews.com - February 27 at 5:58 PM |
| B. Riley Weighs in on Asterias Biotherapeutics Inc's FY2017 Earnings (AST)
www.americanbankingnews.com - February 26 at 1:10 AM |
| Asterias Biotherapeutics (AST) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - February 25 at 2:06 PM |
 | Benzinga's Top Upgrades, Downgrades For February 22, 2018 - Benzinga
www.benzinga.com - February 22 at 3:38 PM |
| Asterias Biotherapeutics Inc (AST) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - February 22 at 9:51 AM |
 | Notable Friday Option Activity: AST, WIFI, PTCT - Nasdaq
www.nasdaq.com - February 17 at 3:37 PM |
| Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer ... - GlobeNewswire (press release)
globenewswire.com - February 17 at 3:37 PM |
| Asterias Expands Global IP Portfolio with New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
finance.yahoo.com - February 15 at 3:38 PM |
| Short Interest in Asterias Biotherapeutics Inc (AST) Expands By 0.1%
www.americanbankingnews.com - January 30 at 2:44 PM |
| Asterias Biotherapeutics (AST) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 19 at 6:02 PM |
| Short Interest in Asterias Biotherapeutics Inc (AST) Declines By 2.6%
www.americanbankingnews.com - January 11 at 2:36 AM |
| Asterias Biotherapeutics' (AST) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - January 8 at 7:26 AM |
| 33 Stocks Moving In Thursday's Mid-Day Session | Benzinga - Benzinga
www.benzinga.com - January 4 at 4:43 PM |
| Asterias Biotherapeutics reports milestone targets for 2018 - Seeking Alpha
seekingalpha.com - January 4 at 4:43 PM |
| Asterias Biotherapeutics Reports Milestone Targets for 2018 - Nasdaq - Nasdaq
www.nasdaq.com - January 4 at 3:43 PM |
| Asterias Biotherapeutics Reports Milestone Targets for 2018
finance.yahoo.com - January 4 at 10:07 AM |
| ETFs with exposure to Asterias Biotherapeutics, Inc. : December 28, 2017
finance.yahoo.com - December 28 at 4:25 PM |
| Asterias Biotherapeutics Inc (AST) Short Interest Up 6.3% in December
www.americanbankingnews.com - December 27 at 6:38 PM |
| Asterias Biotherapeutics, Inc. :AST-US: Earnings Analysis: Q3, 2017 By the Numbers : December 27, 2017
finance.yahoo.com - December 27 at 12:57 PM |
| Wired News – Asterias Reports Enrollment and Dosing of Last Subject in SciStar Trial In Treatment of Severe Spinal Cord Injury
finance.yahoo.com - December 21 at 10:12 AM |
 | BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018 - Business Wire (press release)
www.businesswire.com - December 20 at 3:42 PM |
 | BRIEF-Asterias Biotherapeutics Completes Enrollment Of Entire SCiStar Study
www.reuters.com - December 19 at 4:40 PM |
| Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study - Nasdaq
www.nasdaq.com - December 19 at 10:15 AM |
| Asterias Biotherapeutics Completes Enrollment of Entire SCiStar Study
finance.yahoo.com - December 19 at 10:15 AM |
Asterias Biotherapeutics (NYSEAMERICAN:AST) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Asterias Biotherapeutics (NYSEAMERICAN AST) Stock Chart for Sunday, April, 22, 2018
Loading chart…
